Yes. Renal Cell Carcinoma (RCC) accounts for 95% of malignant neoplasms arising from the kidney. Recent advances in surgical and systemic therapies have significantly changed the management of RCC. High cure rates are seen with localized disease. Targeted therapies have extended the lives of the patients with advanced disease significantly.